Biocryst Pharmaceuticals (BCRX) Capital Expenditures (2010 - 2026)

Biocryst Pharmaceuticals' Capital Expenditures history runs 17 years deep, the most recent figure standing at $608000.0 for Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $608000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 617.45% YoY) and the FY2025 annual result came in at $608000.0, changed N/A from the prior year.
• Capital Expenditures was $608000.0 for Q1 2026 at Biocryst Pharmaceuticals, up from -$1.1 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.1 million in Q2 2025 and bottomed at -$1.6 million in Q4 2023.
• A 5-year average of $160437.5 and a median of $325000.0 in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures slumped 406.84% — and 2025, when it soared 554.89%.
• Biocryst Pharmaceuticals' Capital Expenditures stood at $526000.0 in 2022, then slumped by 406.84% to -$1.6 million in 2023, then jumped by 72.18% to -$449000.0 in 2024, then plunged by 135.63% to -$1.1 million in 2025, then jumped by 157.47% to $608000.0 in 2026.
• Business Quant data shows BCRX's Capital Expenditures at $608000.0 in Q1 2026, -$1.1 million in Q4 2025, and $597000.0 in Q3 2025.